Recognizing the distinct advantages that CRO providers
offer, many pharmaceutical companies have adapted an outsourcing strategy to
increase productivity and offset costs.

GenScript is a contract research organization (CRO) focused
in biological research and drug discovery services. Its service portfolio
includes bio-reagent services, assay development & screening, lead optimization
and antibody drug development.

"After the success of medicinal chemistry outsourcing, biology
CRO is becoming a new trend in drug discovery. We expect a fruitful
collaboration with GenScript in assay development," notes Dr. Li Chen, chief
scientific officer of RRDC in China.

Dr. Frank Zhang, CEO of GenScript, points out that being the
first drug discovery based R&D center established in China by a leading
multinational pharmaceutical company, RRDC is taking the lead again in
expanding into discovery biology arena.

"We appreciate the confidence that RRDC has shown in GenScript,
and believe that the collaboration will mutually benefit us," he adds.